Finance
Drugmaker Indivior drops London listing to cut costs
Published by Global Banking & Finance Review®
Posted on June 2, 2025
2 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on June 2, 2025
2 min readLast updated: January 23, 2026
Indivior exits the London Stock Exchange to cut costs, focusing on Nasdaq as 80% of revenue is U.S.-based. This move aligns with its business strategy.
(Reuters) -Pharma firm Indivior said on Monday it would cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business.
The company, known for its opioid addiction treatment, joins a growing number of firms delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets.
Shares in the company fell 1% in early trade.
Indivior, which listed in London in 2014 after being spun off from Reckitt Benckiser, has seen its shares fall more than 60% from a 2018 peak.
It shifted its primary listing to the U.S. last year and said the London delisting would streamline operations. Indivior follows other firms, including gambling group Flutter, in shifting primary listings away from the UK market.
London, meanwhile, continues to struggle to revive its appeal as a listing destination despite last year's efforts to overhaul listing rules and revive its capital markets.
Chinese fast-fashion retailer Shein chose Hong Kong over London for its IPO, highlighting the continued difficulty in attracting major IPOs, Reuters reported last month.
A string of London-listed firms, including DS Smith and Darktrace, have also delisted following takeovers in recent months.
Indivior said over 80% of its revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes.
The delisting follows a management shake-up, with David Wheadon appointed chair and Joe Ciaffoni CEO this year. In December, the CFO stepped down after pressure from top shareholder Oaktree Capital.
In February, the drugmaker forecast a 17% drop in 2025 net revenue, partly citing weak sales of its film-form medication-assisted therapy for opiate addiction.
(Reporting by Anandita Mehrotra in Bengaluru. Editing by Sonia Cheema and Mark Potter)
Indivior decided to cancel its secondary listing on the London Stock Exchange to reduce costs and streamline operations, maintaining its primary listing on the Nasdaq.
Over 80% of Indivior's revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes.
A growing number of firms are delisting from London due to lower valuations and weak investor appetite, with many opting for U.S. markets instead.
Indivior underwent a management shake-up this year, appointing David Wheadon as chair and Joe Ciaffoni as CEO, following the resignation of the CFO after pressure from a major shareholder.
Indivior's shares have fallen more than 60% from their peak in 2018, reflecting ongoing challenges in the market.
Explore more articles in the Finance category
